Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

18.79
-0.4300-2.24%
Pre-market: 18.75-0.0400-0.21%05:48 EDT
Volume:1.67M
Turnover:31.88M
Market Cap:1.98B
PE:-14.28
High:19.73
Open:19.39
Low:18.66
Close:19.22
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.66
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.30
PE(LYR):-2.64

Loading ...

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Rezolute (RZLT) and Demant (OtherWILLF)

TIPRANKS
·
Mar 25

Sarepta to present Phase 1/2 data for SRP-1001 in FSHD1 and SRP-1003 in DM1

Reuters
·
Mar 25

Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer

TIPRANKS
·
Mar 19

Sarepta provides regulatory update on Amondys 45, Vyondys 53

TIPRANKS
·
Mar 19

Sarepta plans FDA sNDA filings by end of April 2026 to seek traditional approval for AMONDYS 45 and VYONDYS 53

Reuters
·
Mar 19

Sarepta Therapeutics Inc - FDA Confirms Sarepta Can Submit Essence Study and Real-World Evidence for Sndas

THOMSON REUTERS
·
Mar 19

Sarepta Provides Regulatory Update on Amondys 45® and Vyondys 53®

THOMSON REUTERS
·
Mar 19

Sarepta Therapeutics Inc - to Submit Sndas to FDA by End of April 2026 for Traditional Approval

THOMSON REUTERS
·
Mar 19

Sarepta Therapeutics Inc: Requested a Meeting With FDA to Discuss Submitting Supplemental New Drug Applications

THOMSON REUTERS
·
Mar 19

Cantor Fitzgerald Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 17

Sarepta begins ENDEAVOR Cohort 8 trial of ELEVIDYS with sirolimus in 25 non-ambulant Duchenne patients

Reuters
·
Mar 16

Analysts’ Top Healthcare Picks: Edgewise Therapeutics (EWTX), Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 16

Sarepta Therapeutics Is Maintained at Outperform by Mizuho

Dow Jones
·
Mar 13

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT)

TIPRANKS
·
Mar 11

Sarepta Therapeutics Is Maintained at Sell by Citigroup

Dow Jones
·
Mar 10

Sarepta price target raised to $9 from $8 at Citi

TIPRANKS
·
Mar 10

What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

Benzinga
·
Mar 10

BUZZ-Uniqure jumps after FDA vaccines chief Vinay Prasad to step down

Reuters
·
Mar 07

Sarepta Therapeutics (SRPT) Gets a Hold from Evercore ISI

TIPRANKS
·
Mar 03

Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty

TIPRANKS
·
Mar 03